Inhibition of inflammatory bone erosion by constitutively active STAT-6 through blockade of JNK and NF-κB activation

Arthritis and Rheumatism

Volumn 52, Issue 9, 2005, Pages 2719-2729

  Hirayama, Teruhisa ^a   Dai, Simon ^a   Abbas, Sabiha ^a   Yamanaka, Yasuhiro ^a   Abu Amer, Yousef ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 4; OSTEOCLAST DIFFERENTIATION FACTOR; STAT6 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSACTIVATOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; BONE DESTRUCTION; BONE EROSION; CELL DIFFERENTIATION; CONTROLLED STUDY; GEL MOBILITY SHIFT ASSAY; HISTOLOGY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; ANTHRACENES; ARTHRITIS, EXPERIMENTAL; BONE MARROW CELLS; BONE RESORPTION; CARRIER PROTEINS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LEG BONES; MACROPHAGES; MAP KINASE KINASE 4; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NF-KAPPA B; OSTEOCLASTS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SIGNAL TRANSDUCTION; STAT6 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS;

EID: 25444498531     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21286     Document Type: Article

References (53)

1. Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR. Identification of cell types responsible for bone resorption in RA and JRA. Am J Pathol 1998;152:943-51.
2. Isomaki P, Pummonen J. Pro- and anti-inflammatory cytokines in rheumatoid arthritis. Ann Med 1997;29:499-507.
3. Kong YY, Fiege U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402:304-9.
4. Goldring SR, Gravallese EM. Pathogenesis of bone erosion in rheumatoid arthritis. Curr Opin Rheumatol 2000;12:195-9.
5. Romas E, Bakharevski O, Hards DK, Kartsogiannis V, Quinn JM, Ryan PF, et al. Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. Arthritis Rheum 2000;43:821-6.
6. Takayanagi H, Iizuka H, Hideharu J, Juji T, Nakagawa T, Yamamoto A, et al. Involvement of receptor activator of nuclear factor κB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000;43:259-69.
7. Jones DH, Kong YY, Penninger JM. Role of RANKL and RANK in bone loss and arthritis. Ann Rheum Dis 2002;61 Suppl 2:ii32-9.
8. Pettit A, Ji H, Stechow D, Muller R, Goldring S, Choi Y, et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001;159:1689-99.
9. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000;289:1504-8.
10. Lee ZH, Kwack K, Kim KK, Lee SH, Kim HH. Activation of c-Jun N-terminal kinase and activator protein 1 by receptor activator of nuclear factor κB. Mol Pharmacol 2000;58:1536-45.
11. Wong BR, Lee SY, Vologodskia M, Steinman RM, Choi Y. The TRAF family of signal transducers mediates NF-κB activation by the TRANCE receptor. J Biol Chem 1998;273:28335-59.
12. Zhang YH, Heulsmann A, Tondravi MM, Mukherjee A, Abu-Amer Y. Tumor necrosis factor-α (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type I receptor and RANK signaling pathways. J Biol Chem 2000;276:563-8.
13. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J Clin Invest 2001;107:135-42.
14. David JP, Sabapathy K, Hoffmann O, Idarraga MH, Wagner EF. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. J Cell Sci 2002;115:4317-25.
15. Abu-Amer Y, Dowdy SF, Ross FP, Clohisy JC, Teitelbaum SL. TAT fusion proteins containing tyrosine 42-deleted IκBα arrest osteoclastogenesis. J Biol Chem 2001;276:30499-503.
16. Clohisy JC, Roy BC, Biondo C, Frazier E, Willis D, Teitelbaum SL, et al. Direct inhibition of NF-κB blocks bone erosion associated with inflammatory arthritis. J Immunol 2003;171:5547-53.
17. Li X, Udagawa N, Itoh K, Suda K, Suda T, Takahashi N. p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast activation. Endocrinology 2002;143:3105-13.
18. Lee JC, Kumar S, Griswold DE, Underwood DC, Votta BJ, Adams JL. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology 2001;47:185-201.
19. Matsumoto M, Sudo T, Saito E, Osada H, Tsujimoto M. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-κB ligand (RANKL). J Biol Chem 2000;275:31155-61.
20. Su B, Karin M. Mitogen activated protein kinase cascades and regulation of gene expression. Curr Opin Immunol 1996;8:402-12.
21. Watanabe K, Tanaka Y, Morimoto I, Yahata K, Zeki K, Fujihira T, et al. Interleukin-4 as a potent inhibitor of bone resorption. Biochem Biophys Res Commun 1990;172:1035-41.
22. Abu-Amer Y. IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-κB. J Clin Invest 2001;107:1375-85.
23. Takayanagi H, Ogazawara K, Hida S, Chiba T, Murata S, Sato K, et al. T-cell-mediated regulation of osteoclastogenesis by signaling cross-talk between RANKL and IFN-g. Nature 2000;408:600-5.
24. Takeda K, Tanaka T, Shi W, Matsumoto M, Minami M, Kashiwamura S, et al. Essential role of Stat6 in IL-4 signalling. Nature 1996;380:627-30.
25. Oakes SA, Candotti F, Johnston JA, Chen YQ, Ryan JJ, Taylor N, et al. Signaling via IL-2 and IL-4 in JAK3-deficient severe combined immunodeficiency lymphocytes: JAK3-dependent and independent pathways. Immunity 1996;5:605-15.
26. Rolling C, Treton D, Pellegrini S, Galanaud P, Richard Y. IL4 and IL13 receptors share the -yc chain and activate STAT6, STAT3 and STATS proteins in normal human B cells. FEBS Lett 1996;393:53-6.
27. Ohmori Y, Hamilton TA. STAT6 is required for the antiinflammatory activity of interleukin-4 in mouse peritoneal macrophages. J Biol Chem 1998;273:29202-9.
28. Takeda K, Kishimoto T, Akira S. STAT6: its role in interleukin 4-mediated biological functions [review]. J Mol Med 1997;75:317-26.
29. Clohisy DR, Chappel JC, Teitelbaum SL. Bone marrow-derived mononuclear phagocytes autoregulate mannose receptor expression. J Biol Chem 1989;264:5370-7.
30. Han Z, Boyle D, Chang L, Bennett B, Karin M, Yang L, et al. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 2001;108:73-81.
31. Abu-Amer Y, Ross FP, McHugh KP, Livolsi A, Peyron JF, Teitelbaum SL. Tumor necrosis factor-α activation of nuclear transcription factor-κB in marrow macrophages is mediated by c-Src tyrosine phosphorylation of IκBα. J Biol Chem 1998;273:29417-23.
32. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
33. Tetsuka T, Srivastava SK, Morrison AR, Tyrosine kinase inhibitors, genistein and herbimycin A, do not block interleukin-1 β-induced activation of NF-κB in rat mesangial cells. Biochem Biophys Res Commun 1996;218:808-12.
34. Drouet C, Shakhov AN, Jongeneel CV. Enhancers and transcription factors controlling the inducibility of the tumor necrosis factor-α promoter in primary macrophages. J Immunol 1991;147:1694-700.
35. Kip1 induces cell migration. Nat Med 1998;4:1449-52.
36. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 1999;285:1569-72.
37. Schwarze SR, Hruska KA, Dowdy SF. Protein transduction: unrestricted delivery into all cells? [review]. Trends Cell Biol 2000;10:290-5.
38. Ip YT, Davis RJ. Signal transduction by the c-jun N-terminal kinase- from inflammation to development. Curr Opin Cell Biol 1998;10:205-19.
39. Han Z, Boyle DL, Aupperle KR, Bennett B, Manning AM, Firestein GS. Jun N-terminal kinase in rheumatoid arthritis. J Pharmacol Exp Ther 1999;291:124-30.
40. Daniel C, Salvekar A, Schindler U. A gain-of-function mutation in STAT6. J Biol Chem 2000;275:14255-9.
41. Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, et al. Osteoclasts are essential for TNF-α-mediated joint destruction. J Clin Invest 2002;110:1419-27.
42. Hall JP, Merthew E, Davis RJ. cJun N-terminal kinase (JNK) repression during the inflammatory response? Just say no. Proc Natl Acad Sci U S A 2002;97:14022-4.
43. Iotsova V, Caamano J, Loy J, Young Y, Lewin A, Bravo R. Osteopetrosis in mice lacking NFκB1 and NFκB2. Nat Med 1997;3:1285-9.
44. David JP, Sabapathy K, Hoffmann O, Idarraga MH, Wagner EF. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. J Cell Sci 2002;115:4317-25.
45. Dai S, Hirayama T, Abbas S, Abu-Amer Y. The IκB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. J Biol Chem 2004;279:37219-22.
46. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, et aL. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A 2001;98:13681-6.
47. Bruns HA, Schindler U, Kaplan MH. Expression of a constitutively active Stat6 in vivo alters lymphocyte homeostasis with distinct effects in T and B cells. J Immunol 2003;170:3478-87.
48. Han Z, Chang L, Yamanishi Y, Karin M, Firestein GS. Joint damage and inflammation in c-Jun N-terminal kinase 2 knockout mice with joint passive murine collagen-induced arthritis. Arthritis Rheum 2002;46:818-23.
49. Lee FS, Hagler J, Chen ZJ, Maniatis T. Activation of the IκBα kinase complex by MEKK1, a kinase of the JNK pathway. Cell 1997;88:213-22.
50. Huang Q, Yang J, Lin Y, Walker C, Cheng J, Liu Z, et al. Differential regulation of interleukin-1 receptor and Toll-like receptor signaling by MEKK3. Nat Immunol 2004;5:98-103.
51. Tu Z, Lee FS. Subdomain VIII is a specificity-determining region in MEKK1. J Biol Chem 2003;278:48498-505.
52. Ikeda F, Nishimura R, Matsubara T, Tanaka S, Inoue Ji, Reddy SV, et al. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J Clin Invest 2004;114:475-84.
53. Teitelbaum SL. RANKing c-Jun in osteoclast development. J Clin Invest 2004;114:463-5.